Ampligen Down, Probe Aims at Hemispherx Execs' Moves
By Randy Osborne
Thursday, December 20, 2012
Chronic fatigue syndrome patients willing to take Ampligen if it's approved and accept the risks, because it has worked for them in trials faced off against charges of inadequately done studies with less than satisfying overall efficacy signals, during a meeting of the FDA's Arthritis Advisory Committee.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.